药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Boldenone
Oxolinic acid
Ferrous sulfate anhydrous can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Boldenone
Sitafloxacin
Ferrous sulfate anhydrous can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Boldenone
Prulifloxacin
Ferrous sulfate anhydrous can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Boldenone
Pazufloxacin
Ferrous sulfate anhydrous can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Boldenone
Difloxacin
Ferrous sulfate anhydrous can cause a decrease in the absorption of Difloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Boldenone
Sarafloxacin
Ferrous sulfate anhydrous can cause a decrease in the absorption of Sarafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Boldenone
Orbifloxacin
Ferrous sulfate anhydrous can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Boldenone
Enrofloxacin
Ferrous sulfate anhydrous can cause a decrease in the absorption of Enrofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Boldenone
Flumequine
Ferrous sulfate anhydrous can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Boldenone
Nemonoxacin
Ferrous sulfate anhydrous can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Boldenone
Garenoxacin
Ferrous sulfate anhydrous can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Boldenone
Technetium Tc-99m ciprofloxacin
Ferrous sulfate anhydrous can cause a decrease in the absorption of Technetium Tc-99m ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Boldenone
Fleroxacin
Ferrous sulfate anhydrous can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Boldenone
Deferiprone
The serum concentration of Deferiprone can be decreased when it is combined with Ferrous sulfate anhydrous.
Boldenone
Dimercaprol
Dimercaprol may increase the nephrotoxic activities of Ferrous sulfate anhydrous.
17alpha-methyl-4-hydroxynandrolone
Pralsetinib
The serum concentration of Pralsetinib can be increased when it is combined with Troleandomycin.
17alpha-methyl-4-hydroxynandrolone
Satralizumab
The serum concentration of Troleandomycin can be decreased when it is combined with Satralizumab.
17alpha-methyl-4-hydroxynandrolone
Oliceridine
The serum concentration of Oliceridine can be increased when it is combined with Troleandomycin.
17alpha-methyl-4-hydroxynandrolone
Abametapir
The serum concentration of Troleandomycin can be increased when it is combined with Abametapir.
17alpha-methyl-4-hydroxynandrolone
Ripretinib
The serum concentration of Ripretinib can be increased when it is combined with Troleandomycin.